Abstract:

Despite various institutional reforms in the European Union (EU), regulatory procedures for genetically modified (GM) products are still held up by disagreements among experts; claims about a product's safety often correspond to a narrower account of precaution than broader counter-claims from objectors. In the EU, we argue, these conflicts have given practical meaning to the concept of precaution, rather than any explicit interpretation of an a priori principle. Through dynamic tensions between the various claims and accounts of precaution, EU regulatory-expert procedures have identified and addressed more scientific uncertainties than before. Yet decisions about GM products still face legitimacy problems, because they arise fundamentally from the great burden placed on science as the basis for societal choices about agri-biotechnology.